Development and Evaluation of Polymer-bound Glibenclamide Oral Thin Film
- Corresponding Author:
- Raghavendra HL
School of Medicine
P.O. Box 395, Wollega University, Nekemte, Ethiopia
Tel: +251 922253091
E-mail: [email protected]
Received Date: November 24, 2016; Accepted Date: December 19, 2016; Published Date: January 03, 2017
Citation: Raghavendra HL, Kumar GP (2017) Preparation, Characterization and Evaluation of Glibenclamide Oral Thin Film. J Bioequiv Availab 9:324-330. doi: 10.4172/jbb.1000319
Copyright: © 2017 Raghavendra HL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Glibenclamide (GLB) is a second-generation sulfonylurea oral hypoglycemic agent used in the treatment of non-insulin dependent diabetes mellitus. The use of this drug is limited due to its poor dissolution and pharmacokinetic profile. In order to nullify these drawbacks, GLB oral thin films were prepared and evaluated to study the influence of preparatory conditions on the physicochemical properties by using Scanning Electron Microscopy (SEM), Fourier Transform Infra-red Spectroscopy (FTIR) and Differential Scanning Calorimetric (DSC). The surface pH of the GLB thin film was found to be in the range of 6.50 ± 0.10 and it is non-irritant to mucosal lining of the oral cavity. The results of the SEM analysis showed uniform surface morphology with homogenous distribution of GLB pure drug in PVP matrix. The in vitro drug release profile at pH 5.0 and 7.5 revealed sustained release patterns for a period of 8 h. The GLB oral thin film showed an enhanced in vivo insulin release profiles as compared to pure GLB drug. Thus, the results of the present study revealed that, the prepared GLB oral thin film can be used as alternative strategy to deliver glibenclamide for diabetes mellitus as it showed a significant role in increasing in vitro dissolution and in vivo insulin release profiles.